Travere Therapeutics
3611 Valley Centre Drive
Suite 300
San Diego
California
92130
United States
Tel: 888-969-7879
Website: https://travere.com/
353 articles about Travere Therapeutics
-
Retrophin's R&D Head Resigns to Helm Unnamed Biotech Startup
10/7/2016
-
Retrophin Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
10/3/2016
-
Retrophin To Present At The Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series
9/15/2016
-
Retrophin Announces Positive Top-Line Results From Phase II DUET Study Of Sparsentan In Patients With Focal Segmental Glomerulosclerosis
9/7/2016
-
Ligand Partner Retrophin Announces Positive Top-Line Results From Phase II DUET Study Of Sparsentan In Patients With Focal Segmental Glomerulosclerosis
9/7/2016
-
Retrophin Appoints Neil Mcfarlane Chief Operating Officer
8/15/2016
-
Retrophin To Report Second Quarter 2016 Financial Results
7/22/2016
-
Retrophin Appoints Roy D. Baynes, M.D., Ph.D., To Board Of Directors
7/20/2016
-
Retrophin Announces New Data From Physician-Initiated Treatment With RE-024 At The 20th International Congress Of Parkinson’s Disease And Movement Disorders
6/23/2016
-
Retrophin Pays Up to $24 Million for Rights to PBC Candidate from Asklepion
6/21/2016
-
Retrophin To Present At The Barclays Global Healthcare Conference
3/4/2016
-
Retrophin To Present At The Cowen and Company 36th Annual Health Care Conference
2/24/2016
-
Retrophin Receives European Orphan Drug Designation For Sparsentan For The Treatment Of Focal Segmental Glomerulosclerosis
11/16/2015
-
Retrophin Announces Research Collaboration With The Grace Wilsey Foundation And The Warren Family Research Center For Drug Discovery And Development At University of Notre Dame
11/5/2015
-
Retrophin To Present At The Leerink Partners 4th Annual Rare Disease Roundtable
9/17/2015
-
Retrophin Sues Ousted CEO Martin Shkreli for $65 Million
8/17/2015
-
Former Retrophin CEO Nabs $90 Million for Startup Turing Pharma
8/10/2015
-
Retrophin Reports Second Quarter 2015 Financial Results
8/5/2015
-
Retrophin To Report Second Quarter 2015 Financial Results
7/22/2015
-
Retrophin Closes Sale Of Priority Review Voucher
7/7/2015